A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

Description

The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 9 visits.

Conditions

Healthy, Overweight, Obesity, Type 2 Diabetes

Talk to us

Study Overview

On this page

Study Details

Study overview

The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 9 visits.

A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

Condition
Healthy
Intervention / Treatment

-

Contacts and Locations

Daytona Beach

Fortrea Clinical Research Unit, Daytona Beach, Florida, United States, 32117

Dallas

Fortrea Clinical Research Unit, Dallas, Texas, United States, 75247

San Antonio

Endeavor Clinical Trials, San Antonio, Texas, United States, 78240

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have no significant body weight change for the 3 months prior to screening
  • * Are considered healthy
  • * Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening
  • * Have a BMI of 27 to 45 kg/m2 at screening
  • * Have a BMI of 25 to 45 kg/m2 at screening
  • * Have type 2 diabetes
  • * Have hemoglobin A1C (HbA1c) ≥7.0% and ≤10.5% at screening
  • * Have a BMI of 27 to 45 kg/m2 at screening
  • * Have had an acute cardiovascular condition within the past 6 months prior to screening
  • * Have liver disease or pancreatitis
  • * Have used medications for weight loss within the 3 months prior to screening
  • * Have any form of diabetes
  • * Have type 1 diabetes

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Eli Lilly and Company,

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

2026-04